Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer - Full Text View

Purpose

RATIONALE: Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced, unresectable, or metastatic pancreatic cancer.

Condition	Intervention	Phase
Pancreatic Cancer	Drug: perifosine	Phase II

MedlinePlus related topics:

Cancer Pancreatic Cancer

Drug Information available for:

Pancrelipase Ultrase Perifosine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label

Official Title:	Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:

July 2003

Detailed Description:

OBJECTIVES:

Determine the activity of perifosine, in terms of objective response, in patients with locally advanced, unresectable, or metastatic pancreatic cancer.
Determine the response duration, progression-free survival, and overall survival of patients treated with this drug.
Determine the toxicity of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral perifosine every 6 hours for a total of 6 doses and then once daily in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 3 years.

PROJECTED ACCRUAL: A total of 35-84 patients will be accrued for this study within 21 months.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed adenocarcinoma of the pancreas
Locally advanced, unresectable, or metastatic disease
Measurable disease
No known brain metastases

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

ECOG 0-1

Life expectancy

Not specified

Hematopoietic

WBC at least 3,500/mm^3
Platelet count at least 100,000/mm^3
Hemoglobin at least 10 g/dL

Hepatic

AST no greater than 2 times upper limit of normal (ULN)
Bilirubin no greater than 2 times ULN

Renal

Creatinine no greater than 1.4 mg/dL

Cardiovascular

No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No ongoing or active infection
No psychiatric illness or social situation that would preclude study compliance
No other concurrent illness that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

No prior chemotherapy for pancreatic cancer
More than 6 months since prior chemotherapy for other diseases

Endocrine therapy

Not specified

Radiotherapy

At least 4 weeks since prior radiotherapy and recovered

Surgery

At least 4 weeks since prior surgery and recovered

Other

No other concurrent investigational agents for pancreatic cancer
No concurrent combination antiretroviral therapy for HIV-positive patients

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00059982

Locations


United States, Illinois
	CCOP - Carle Cancer Center
	Urbana, Illinois, United States, 61801

United States, Indiana
	CCOP - Northern Indiana CR Consortium
	South Bend, Indiana, United States, 46601

United States, Iowa
	CCOP - Iowa Oncology Research Association
	Des Moines, Iowa, United States, 50309-1016

United States, Massachusetts
	Tufts - New England Medical Center
	Boston, Massachusetts, United States, 02111

United States, Minnesota
	CCOP - Duluth
	Duluth, Minnesota, United States, 55805
	CCOP - Metro-Minnesota
	Saint Louis Park, Minnesota, United States, 55416
	Mayo Clinic Cancer Center
	Rochester, Minnesota, United States, 55905

United States, New York
	MBCCOP-Our Lady of Mercy Cancer Center
	Bronx, New York, United States, 10466

United States, North Dakota
	CCOP - Merit Care Hospital
	Fargo, North Dakota, United States, 58122

United States, Texas
	CCOP - Scott and White Hospital
	Temple, Texas, United States, 76508

Sponsors and Collaborators

Eastern Cooperative Oncology Group

National Cancer Institute (NCI)

Investigators


Study Chair:	Robert de W. Marsh, MD	University of Florida

Investigator:	Caio Max S. Rocha Lima, MD	H. Lee Moffitt Cancer Center and Research Institute

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications of Results:

Marsh Rde W, Lima CM, Levy DE, Mitchell EP, Rowland KM Jr, Benson AB 3rd. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007 Feb;30(1):26-31.

Study ID Numbers:	CDR0000298994, ECOG-E1202
First Received:	May 6, 2003
Last Updated:	July 23, 2008
ClinicalTrials.gov Identifier:	NCT00059982
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

adenocarcinoma of the pancreas

stage II pancreatic cancer

stage III pancreatic cancer

stage IV pancreatic cancer

Study placed in the following topic categories:

Digestive System Diseases

Digestive System Neoplasms

Pancreatic Neoplasms

Endocrine System Diseases

Pancreatic Diseases

Gastrointestinal Neoplasms

Endocrinopathy

Adenocarcinoma

Pancrelipase

Endocrine Gland Neoplasms

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on November 30, 2008

Sponsors and Collaborators:	Eastern Cooperative Oncology Group National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00059982